NT-proBNP A new test for Diagnosis, Prognosis and Management of Congestive Heart Failure

US Cardiology, 2004;1(1):1-5

Introduction

With nearly 500,000 new cases per year and direct costs estimated as high as US$38 billion annually, congestive heart failure (CHF) has become a major priority in modern medicine. This crisis will continue to grow as the population ages, thus the discernment of new diagnostic and therapeutic strategies to improve prognosis and reduce costs is critical.1

The irony is that therapies with great benefit for patients with CHF exist, such as angiotensin converting enzyme (ACE) inhibitors and beta-blockers. However, these agents are under-utilized, and when employed may be dosed inadequately.2,3 Accordingly, a widely available and accurate diagnostic tool to identify those with CHF would be essential in order to identify those patients eligible for proven therapies in CHF. Such a diagnostic tool for early diagnosis would theoretically lead to earlier initiation of these beneficial medicines while potentially assisting in chronic out-patient management of such patients. As CHF is the leading cause of hospitalization in adults over 65, achieving such early diagnosis and initiation of therapy would thus prevent hospitalizations and reduce the considerable costs of CHF.4

Markers of cardiac neurohormonal activation, particularly B-type natriuretic peptides, have been identified as possible tools to identify and treat patients with CHF.While most studies to date have focused on the diagnostic utility of B-type natriuretic peptide (BNP), more recent research has revealed that the amino-terminal fragment of the BNP molecule (NT-proBNP), a marker with great diagnostic and prognostic power, is a marker for CHF. Recently, a new automated immunoassay has made NT-proBNP testing a reality for diagnostic, prognostic, and possibly therapeutic, purposes in CHF.5 This paper reviews some of the growing evidence behind the use of NT-proBNP in patients with CHF.

Biology of Natriuretic Peptides

The natriuretic peptides are a family of molecules consisting of several structurally-related hormones. At present, the natriuretic peptide family includes atrial natriuretic peptide (ANP), B-type (or brain) natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and dendroaspis natriuretic peptide (DNP).

References:
  1. O’Connell J B and Bristow M,“Economic impact of heart failure in the United States: a time for a different approach”, J. Heart Lung Transplant, (1994), 13: p. S107.
  2. CONSENSUS Trial Study Group,“Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)”, N. Eng. J. Med. (1987), 316 (23): p. 1,429.
  3. Packer M, Bristow M R, Cohn J N, et al., “The effect of carvedilol on morbidity and mortality in patients with chronic heart failure”, US Carvedilol Heart Failure Study Group, N. Eng. J. Med. (1996), 334 (21): p. 1,349.
  4. Rich M W and Nease R F,“Cost-effectiveness analysis in clinical practice.The case of heart failure”, Arch. Intern. Med. (1999), 159: p. 1,690.
  5. Hobbs F D, Davis R C, Roalfe A K, et al., “Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations”, BMJ, (2002), 324: p. 1,498.
  6. Levin E R, Gardner D G and Samson W K,“Natriuretic peptides”, N. Eng. J. Med. (1998), 339: p. 321.
  7. Nakagawa O, Ogawa Y, Itoh H et al.,“Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload”, J. Clin. Invest. (1995), 96: p. 1,280.
  8. Davis M, Espiner E, Richards G et al.,“Plasma brain natriuretic peptide in assessment of acute dypnoea”, Lancet, (1994), 343: p. 440.
  9. Yamamoto K, Burnett J C Jr, Jougasaki M, et al., “Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy”, Hypertension, (1996), 28: p. 988.
  10. Yeo K T,Wu A H, Apple F S, et al., “Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay”, Clin. Chim.Acta. (2003), 338: p. 107.
  11. Bay M, Kirk V, Parner J, et al.,“NT-proBNP: a new diagnostic screening tool to differentiate patients with a normal and reduced systolic function”, Heart, (2003), 89: p. 150.
  12. Lainchbury J G, Campbell E, Frampton C M, et al., “Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath”, J.Am. Coll. Cardiol. (2003), 42: p. 728.
  13. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al., “N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction”, Eur. J. Heart Fail. (2004), 6: p. 301.
  14. Bettencourt P,“NT-proBNP and BNP: biomarkers for heart failure management”, Eur. J. Heart Fail. (2004), 6: p. 359.
  15. Januzzi J L, Camargo C A,Anwaruddin S, et al.,“N-terminal ProBNP for Emergency Evaluation of Shortness of Breath:The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study”, J. Am. Coll. Cardiol. (2004), 43 (5): p. 235(a).
  16. Mueller T, Gegenhuber A, Poelz W and Haltmayer M, “Head-to-head comparison of the diagnostic utility of BNP and NTproBNP in symptomatic and asymptomatic structural heart disease”, Clin. Chim.Acta. (2004), 341: p. 41.
  17. Prontera C, Emdin M, Zucchelli G C, et al., “Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide”, Clin. Chem. Lab. Med. (2004), 42: p. 37.
  18. Seino Y, Ogawa A,Yamashita T, et al., “Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure”, Eur. J. Hear. Fail. (2004), 6: p. 295.
  19. Hunt P J, Richards A M, Nicholls M G, et al.,“Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment”, Clin. Endocrinol. (1997), 47: p. 287.
  20. Tang W H W, Girod J P, Lee M J, et al.,“Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic heart failure”, Circulation, (2003), 108: p. 2,964.
  21. McCullough P A, Philbin E F, Spertus J A et al.,“Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study”, J.Am. Coll. Cardiol. (2002), 39: p. 60.
  22. Fisher C, Berry C, Blue L, et al., “N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic renal failure”, Heart, (2003), 89: p. 879.
  23. Groenning B A, Raymond I, Hildebrandt P R, et al.,“Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population”, Heart, (2004), 90: p. 297.
  24. Richards A M, Doughty R, Nicholls M G, et al.,“Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction”, Australia-New Zealand Heart Failure Group, J.Am. Coll. Cardiol. (2001), 37 (7): p. 1,781.
  25. Richards A M, Nicholls M G,Yandle T G, et al., “Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction”, Circulation, (1998), 97: p. 1,921.
  26. Gardner R S, Ozalp F, Murday A J, et al., “N-terminal pro-brain natriuretic peptide in patients with advanced heart failure”, Eur. Heart J. (2003), 24: p. 1,735.
  27. Troughton R W, Frampton C M,Yandle T G, et al.,“Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations”, Lancet, (2000), 355: p. 1,126.
  28. James S K, Lindahl B, Siegbahn A, et al., “N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: GUSTO IV substudy”, Circulation, (2003),108: p. 275.
  29. Jernberg T, Stridsberg M,Venge P and Lindahl B,“N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation”, J.Am. Coll. Cardiol. (2002), 40: p. 437.
  30. Jernberg T, Lindahl B,Venge P, et al., “N-terminal pro brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of invasive strategy in unstable coronary artery disease”, J.Am. Coll. Cardiol. (2002), 42: p. 1,909.
  31. Kucher N, Printzen G, Doernhoefer T, et al., “Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism”, Circulation, (2003), 107: p. 1,576.

Suggest a topic for future coverage